Decreased Homovanilic Acid in Cerebrospinal Fluid Correlates with Impaired Neuropsychologic Function in HIV-1-Infected Patients

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical neuropharmacology

• Publication date

  2000-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00002826-200007000-00004PMID 11020122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nigral degeneration in acquired immune deficiency syndrome (AIDS)

  2004cited by this paper
• Practitioner's Guide to the Neuropsychiatry of HIV/AIDS

  1999cited by this paper
• HIV dementia and the basal ganglia.

  1997cited by this paper
• Monoamine metabolite levels in CSF of SIV‐infected rhesus monkeys (Macaca mulatta)

  1997cited by this paper
• The neuropathogenesis of the AIDS dementia complex.

  1997cited by this paper
• Levodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromes

  1996cited by this paper
• PET Measurements of Neuroreceptor Occupancy by Typical and Atypical Neuroleptics

  1996cited by this paper
• Deep gray matter structures in HIV infection: a proton MR spectroscopic study.

  1996cited by this paper
• Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS

  1996cited by this paper
• [Movement disorders and AIDS].

  1996cited by this paper
• Dementia and cognitive changes in Huntington's disease.

  1995cited by this paper
• Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report.

  1994cited by this paper
• Neuropsychological characterization of the AIDS dementia complex and rationalization of a test battery.

  1994cited by this paper
• Cerebrospinal fluid dopamine in HIV‐1 infection

  1994cited by this paper
• Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial

  1993cited by this paper
• Cerebrospinal fluid catecholamine metabolites in HIV‐infected patients

  1991cited by this paper
• Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection

  1991cited by this paper
• Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications.

  1991cited by this paper
• Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy.

  1991cited by this paper
• Cognitive function in Parkinson's disease: from description to theory.

  1990cited by this paper
• Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates

  1988cited by this paper
• Movement disorders and AIDS

  1987cited by this paper
• The metabolic pathology of the AIDS dementia complex

  1987cited by this paper
• The AIDS dementia complex: II. Neuropathology

  1986cited by this paper
• The AIDS dementia complex: I. Clinical features

  1986cited by this paper
• Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

  1986cited by this paper
• Subcortical Dementia: Review of an Emerging Concept

  1984cited by this paper
• Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid

  1980cited by this paper
• The `subcortical dementia' of progressive supranuclear palsy

  1974cited by this paper

• Mutational effects of the asparagine198 and glutamate223 residues on the human norepinephrine transporter on basal and HIV-1 Tat protein-induced inhibition of dopamine transport.

  2025cites this paper
• Exploring new frontiers in the treatment of HIV-associated neurocognitive disorder.

  2025cites this paper
• Impact of HIV-1 Tat protein on methamphetamine-induced inhibition of vesicular monoamine transporter2-mediated dopamine transport and methamphetamine conditioned place preference in HIV-1 Tat transgenic mice.

  2024cites this paper
• Modulation of tenofovir by probenecid: Impact on drug, interleukin-1β, and dopamine concentration in the prefrontal cortex and cerebellum.

  2024cites this paper
• Identification of pyrimidine structure-based compounds as allosteric ligands of the dopamine transporter as therapeutic agents for NeuroHIV.

  2024cites this paper
• Deprenyl reduces inflammation during acute SIV infection

  2022cites this paper
• SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice.

  2022cites this paper
• Novel Allosteric Modulator Southern Research Institute-32743 Reverses HIV-1 Transactivator of Transcription-Induced Increase in Dopamine Release in the Caudate Putamen of Inducible Transactivator of Transcription Transgenic Mice

  2022cites this paper
• Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function

  2022cites this paper
• HIV-Associated Apathy/Depression and Neurocognitive Impairments Reflect Persistent Dopamine Deficits

  2021cites this paper
• Lower CSF Homovanillic Acid Relates to Higher Burden of Neuroinflammation and Depression in People with HIV Disease.

  2020cites this paper
• Dopaminergic impact of cART and anti-depressants on HIV Neuropathogenesis in older adults.

  2019cites this paper
• Diagnostic and prognostic biomarkers for HAND

  2019cites this paper
• Effects of Human Dopamine Transporter (DAT) Mutations and Novel Allosteric Modulatory Compounds in Disrupting HIV-1 Tat-DAT Protein Interaction

  2019cites this paper
• Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders

  2018cites this paper
• HIV, Tat and dopamine transmission.

  2017cites this paper
• Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice

  2017cites this paper
• Selective Behavioral Alterations In The HIV-1 Transgenic Rat: Implications For Diagnosis Of Pediatric HIV-1

  2016cites this paper
• A Gap in Time: Extending our Knowledge of Temporal Processing Deficits in the HIV-1 Transgenic Rat

  2016cites this paper
• Progression of temporal processing deficits in the HIV-1 transgenic rat

  2016cites this paper
• Exercise–Cognition Interaction

  2016cites this paper
• Beyond the Catecholamines Hypothesis for an Acute Exercise–Cognition Interaction: A Neurochemical Perspective

  2016cites this paper
• HIV-1 proteins, Tat and gp120, target the developing dopamine system.

  2015cites this paper
• Modeling Deficits in Attention, Inhibition, and Flexibility in HAND

  2014cites this paper
• Neonatal intrahippocampal HIV‐1 protein Tat1–86 injection: neurobehavioral alterations in the absence of increased inflammatory cytokine activation

  2014cites this paper
• Dopamine Receptor Activation Increases HIV Entry into Primary Human Macrophages

  2014cites this paper
• HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations

  2013cites this paper
• Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction.

  2013cites this paper
• When Human Immunodeficiency Virus Meets Chemokines and Microglia: Neuroprotection or Neurodegeneration?

  2013cites this paper
• Time and Time Again: Temporal Processing Demands Implicate Perceptual and Gating Deficits in the HIV-1 Transgenic Rat

  2013cites this paper
• Title Systems analysis of human brain gene expression : mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer ¿ s disease

  2013cites this paper
• Modeling HIV-1-Associated Neurocognitive Disorders and the Therapeutic Effects of the Phytoestrogen Metabolite S-Equol in the HIV-1 Transgenic Rat

  2013cites this paper
• Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer’s disease

  2013cites this paper
• Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

  2012cites this paper
• Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

  2012influential citation
• Drugs of Abuse, Dopamine, and HIV-Associated Neurocognitive Disorders/HIV-Associated Dementia

  2011cites this paper
• Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance

  2011cites this paper
• HIV Infection and Movement Disorders

  2010cites this paper
• Hyperdopaminergic tone in HIV‐1 protein treated rats and cocaine sensitization

  2010cites this paper
• Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses

  2010cites this paper
• Neurocognitive disturbances in HIV

  2008cites this paper
• Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

  2008cites this paper
• A test of the catecholamines hypothesis for an acute exercise-cognition interaction.

  2008cites this paper
• Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV

  2008cites this paper
• Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons

  2007cites this paper
• Neurocognitive assessment of persons with HIV disease.

  2007cites this paper
• Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra.

  2006cites this paper
• HIV-induced chorea: evidence for basal ganglia dysregulation by SPECT.

  2005cites this paper
• HIV–induced chorea

  2005cites this paper
• Effects of Acute Lorazepam Administration on Aminergic Activity in Normal Elderly Subjects: Relationship to Performance Effects and Apolipoprotein Genotype

  2004cites this paper
• HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat.

  2003cites this paper
• Human immunodeficiency virus‐1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function

  2002cites this paper
• Executive Control Function in Psychiatric and Medical Illness

  2002cites this paper